
Pharmacy Practice in Focus: Oncology
- November 2020
- Volume 2
- Issue 5
CE: Managing Chronic Immune Thrombocytopenia: Opportunities for Oncology Pharmacists to Optimize Patient Care
Key Takeaways
- Participants will gain insights into the epidemiology, pathophysiology, diagnosis, and impact of chronic ITP in cancer patients.
- The program provides analysis of the latest efficacy and safety data, including dosing and administration of current pharmacologic treatments for chronic ITP.
This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.
This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Examine the epidemiology, pathophysiology, diagnosis, and impact of chronic immune thrombocytopenia (ITP) among patients with cancer
- Analyze the latest efficacy and safety data as well as dosing and administration of current pharmacologic treatments of chronic ITP
- Illustrate the role of the oncology pharmacist in the management of chronic ITP
FACULTY:
Julianne O. Darling, PharmD, BCOP
Outpatient Oncology Clinical Pharmacist , Indiana University Simon Cancer Center, Indianapolis, Indiana
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: October 30, 2020
EXPIRATION DATE: November 30, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
almost 5 years ago
Essential Updates in Acute Graft-Versus-Host Diseasealmost 5 years ago
Cancer Care During the COVID-19 Pandemicalmost 5 years ago
Spotlight on BTK Inhibitors in the Management of B-Cell Malignanciesalmost 5 years ago
Bispecific Antibodies: The Next Generation of Immunotherapyalmost 5 years ago
Recent Developments in Therapeutics for GIST, Non–Small Cell Lung CancerNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.